Aliases:This biomarker is also known as:
- Myc proto-oncogene protein,
- Class E basic helix-loop-helix protein 39,
- avian myelocytomatosis viral oncogene homolog,
- v-myc myelocytomatosis viral oncogene homolog (avian),
- myc-related translation/localization regulatory factor,
- myc proto-oncogene protein,
- Proto-oncogene c-Myc,
- v-myc avian myelocytomatosis viral oncogene homolog,
- Transcription factor p64,
The oncogenic protein MYC, previously known as c-MYC, is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It participates in the regulation of gene transcription of specific target genes. MYC binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Mutations, overexpression, rearrangement and translocation of the MYC gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. Evidence shows that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
MYC, or c-MYC, amplification has been implicated in primary breast cancer through multiple studies over the years. The MYC amplification correlates with disease progression and recurrence.
MYC was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
|QA State:||Under Review|
MYC is an important oncogene in lung cancer. It is expressed in a large number of non-small cell lung cancers (NSCLCs). Gene amplification at 8q24 and resultant increased expression of MYC is a common occurrence in carcinomas. It leads to increased formation of the MYC:Max heterodimer transcription factors that alter gene expression in large part by recruiting histone-modifying enzymes.
When assessed as a candidate biomarker signature predictive of lung cancer, the sensitivity of presence of abnormality in TP63, MYC, CEP3, and CEP6 was 82% and specificity was 58%. The receiver operating characteristic (ROC) curves show the added value of histology and epidemiological information, ultimately achieving an area under the curve of 92.6%. The demographic information represents gender, age, pack years of smoking history, and smoking status. The differences between the curves were significant between demographics vs. demographics and cytology (p = 0.02) or vs. demographics, cytology and 4 FISH biomarkers (TP63, MYC, CEP3, CEP6) (p = 0.002). Although showing a trend, the difference was not significant between demographics and cytology vs. demographics, histology and 4 FISH biomarkers (p = 0.11).
- Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.
- The State of Molecular Biomarkers for the Early Detection of Lung Cancer.
- Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.